Literature DB >> 22421528

Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial.

Ken Nagata1, Eriko Yokoyama, Takashi Yamazaki, Daiki Takano, Tetsuya Maeda, Satoshi Takahashi, Yasuo Terayama.   

Abstract

Previous clinical trials suggest that the traditional Japanese medicine yokukansan has beneficial effects on the behavioral and psychological symptoms of dementia (BPSD). The present study was conducted to elucidate the efficacy of yokukansan on BPSD in patients with vascular dementia. Thirteen Japanese patients (9 men and 4 women) who were diagnosed as having vascular dementia (VaD) according to the diagnostic criteria of NINDS-AIREN were subjected to the open-label clinical trial in which yokukansan (7.5g/day) has been given for 4 weeks. Their mean age was 71.2±6.5 years. The BPSD was evaluated using the Neuropsychiatric Inventory (NPI), cognitive function was evaluated by the Mini-Mental State Examination (MMSE), the activities of daily living was evaluated by Barthel index (BI) and Disability Assessment for Dementia (DAD), and the extrapyramidal signs were evaluated by United Parkinson's Disease Rating Scale (UPDRS). The mean NPI was 33.0±17.3 and 23.6±13.9 for the baseline and after treatment, respectively. It was significantly improved after treatment (p<0.05). In the NPI-subcategories, there was a significant improvement in agitation and disinhibition after the treatment. There was no significant change in MMSE, BI, DAD or UPDRS before and after the treatment. There was no adverse effect during the treatment period. The present results suggest that yokukansan is beneficial for the treatment of BPSD in VaD patients.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421528     DOI: 10.1016/j.phymed.2012.02.008

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  16 in total

1.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Tohyama; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shyuichi Ueno; Sachiko Ezoe; Kenta Murotani; Syuzo Hoshino; Haruo Seno
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

Review 2.  New possibility of traditional Chinese and Japanese medicine as treatment for behavioral and psychiatric symptoms in dementia.

Authors:  Fan-Chin Kung; Ryouhei Ishii; Hsing-Cheng Liu; Masatoshi Takeda
Journal:  Clin Interv Aging       Date:  2012-10-04       Impact factor: 4.458

3.  Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Tsuyoshi Miyaoka; Motohide Furuya; Jun Horiguchi; Rei Wake; Sadayuki Hashioka; Masaya Thoyama; Kenta Murotani; Norio Mori; Yoshio Minabe; Masaomi Iyo; Shuichi Ueno; Sachiko Ezoe; Syuzo Hoshino; Haruo Seno
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-14       Impact factor: 2.629

4.  Yokukansan, a kampo medicine, protects PC12 cells from glutamate-induced death by augmenting gene expression of cystine/glutamate antiporter system Xc-.

Authors:  Hitomi Kanno; Zenji Kawakami; Kazushige Mizoguchi; Yasushi Ikarashi; Yoshio Kase
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

5.  Yokukansan enhances the proliferation of B65 neuroblastoma.

Authors:  Yoshihiko Nakatani; Taku Amano; Hikaru Yamamoto; Norio Sakai; Minoru Tsuji; Hiroshi Takeda
Journal:  J Tradit Complement Med       Date:  2016-02-22

Review 6.  Serotonin Receptor Binding Characteristics of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook.

Authors:  Yasushi Ikarashi; Kyoji Sekiguchi; Kazushige Mizoguchi
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

Review 7.  Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects.

Authors:  Kazushige Mizoguchi; Yasushi Ikarashi
Journal:  Front Pharmacol       Date:  2017-03-21       Impact factor: 5.810

8.  Analgesic Effect of Combined Therapy with the Japanese Herbal Medicine "Yokukansan" and Electroacupuncture in Rats with Acute Inflammatory Pain.

Authors:  Nachi Ebihara; Hideshi Ikemoto; Naoki Adachi; Takayuki Okumo; Taro Kimura; Kanako Yusa; Satoshi Hattori; Atsufumi Manabe; Tadashi Hisamitsu; Masataka Sunagawa
Journal:  Medicines (Basel)       Date:  2021-06-17

Review 9.  Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions.

Authors:  Hideki Okamoto; Masaomi Iyo; Keigo Ueda; Cheolsun Han; Yoshiro Hirasaki; Takao Namiki
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-12       Impact factor: 2.570

10.  Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function.

Authors:  Kenji Takeyoshi; Masatake Kurita; Satoshi Nishino; Mika Teranishi; Yukio Numata; Tadahiro Sato; Yoshiro Okubo
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.